Adenylate cyclase gene therapy (Renova)

N/A

Report date: 2023/10/26 16:15:07

Base Information

Drug NameAdenylate cyclase gene therapy (Renova)
Drug Alias Name腺苷酸环化酶基因治疗 - RenovaRT-100Ad5.hAC6
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adenoviral vector > Ad5 vector
Mechanisms of ActionATP stimulants
TargetsATP
Therapy Area/IndicationsHeart Failure
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesRenova Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesRenova Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsHeart Failure

Other Information

ATC CodeN/A
Related LinksN/A